Sivik Global Healthcare LLC Sells 30,000 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Sivik Global Healthcare LLC trimmed its position in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 15.0% in the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 170,000 shares of the company’s stock after selling 30,000 shares during the period. Sivik Global Healthcare LLC’s holdings in Teva Pharmaceutical Industries were worth $3,063,000 as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of the company. Oppenheimer & Co. Inc. grew its holdings in shares of Teva Pharmaceutical Industries by 9.6% during the first quarter. Oppenheimer & Co. Inc. now owns 13,522 shares of the company’s stock valued at $191,000 after buying an additional 1,180 shares during the last quarter. Sei Investments Co. increased its holdings in shares of Teva Pharmaceutical Industries by 0.9% in the first quarter. Sei Investments Co. now owns 457,322 shares of the company’s stock valued at $6,453,000 after purchasing an additional 4,000 shares during the period. State Board of Administration of Florida Retirement System raised its stake in shares of Teva Pharmaceutical Industries by 13.4% in the first quarter. State Board of Administration of Florida Retirement System now owns 62,018 shares of the company’s stock worth $875,000 after purchasing an additional 7,335 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. lifted its holdings in shares of Teva Pharmaceutical Industries by 36.3% during the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 627,691 shares of the company’s stock worth $8,857,000 after purchasing an additional 167,097 shares during the period. Finally, Vanguard Group Inc. boosted its position in Teva Pharmaceutical Industries by 3.5% in the first quarter. Vanguard Group Inc. now owns 825,537 shares of the company’s stock valued at $11,648,000 after buying an additional 28,071 shares during the last quarter. 54.05% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on TEVA shares. StockNews.com upgraded Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research report on Thursday, October 17th. UBS Group raised their price objective on shares of Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the company a “buy” rating in a research note on Tuesday, September 3rd. Barclays lifted their price target on Teva Pharmaceutical Industries from $22.00 to $25.00 and gave the stock an “overweight” rating in a report on Wednesday, October 23rd. Finally, JPMorgan Chase & Co. boosted their target price on Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the company a “neutral” rating in a report on Monday, October 21st. Two investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Teva Pharmaceutical Industries has a consensus rating of “Moderate Buy” and a consensus price target of $19.67.

Teva Pharmaceutical Industries Price Performance

Teva Pharmaceutical Industries stock traded down $0.14 during mid-day trading on Thursday, hitting $16.80. 342,347 shares of the company were exchanged, compared to its average volume of 9,214,599. Teva Pharmaceutical Industries Limited has a 12-month low of $8.64 and a 12-month high of $19.31. The company has a market capitalization of $19.03 billion, a P/E ratio of -19.94, a PEG ratio of 1.34 and a beta of 0.87. The business’s 50 day simple moving average is $17.84 and its two-hundred day simple moving average is $17.20. The company has a debt-to-equity ratio of 2.57, a current ratio of 0.89 and a quick ratio of 0.61.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.